BioSpace News Archive

The World Health Organization states that there will be 22 million new cases of cancer in the next two decades, which is a staggering figure.

Growing use of technologically advanced devices in bowel management is one of the key factors predicted to drive the demand opportunities in the global skin barriers market during the tenure of 2020–2030.

Sartorius Stedim Biotech, a leading partner of the biopharma industry, closed the first nine months of 2020 with significant double-digit growth rates in sales revenue and earnings.

Vifor Pharma and Cara Therapeutics, Inc. announced that both companies have signed a license agreement for commercialization of Korsuva Injection for the treatment of chronic kidney disease-associated pruritus in the US dialysis market for non-Fresenius Medical Care clinics under a Cara 60%, Vifor Pharma 40% profit-sharing arrangement.

Neuromod Devices Limited, the Irish medical device company specialising in the treatment of tinnitus, a chronic condition that affects 10-15% of the global population and commonly described as ‘ringing in the ears’, announces it has raised €10.5 million in an oversubscribed Series B financing.

RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services reported it has executed a partnership agreement with Adventist Health to create an outpatient imaging joint venture in Simi Valley, California to initially include three outpatient facilities.

Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced it is increasing full-year 2020 guidance and now anticipates revenues greater than €80 million.

Caris’ collaborative network focused on expanding the application of precision medicine in oncology supports Winship’s enterprising approach to research leading to transformative discoveries in cancer care and treatment

In PNEU-PATH (V114-016) and PNEU-DAY (V114-017), V114 Met Primary Immunogenicity Objectives and Elicited A Strong Immune Response for All 15 Serotypes Included in the Vaccine, Including 22F and 33F - Serotypes Unique to V114

Parexel announced that its Biotech division has entered into a strategic collaboration with Synairgen plc, a respiratory drug discovery and development company, to conduct a pivotal phase III study of an interferon beta treatment for patients hospitalized with COVID-19.